Among many traditional medicines, Ganoderma has been used in Asian countries for over two millennia as a traditional medicine for maintaining vivacity and longevity. Research on various metabolic activities of Ganoderma have been performed both in vitro and in vivo studies. However, it is debatable whether Ganoderma is a food supplement for health maintenance or a therapeutic "drug" for medical purposes. Over the past two decades, the Ganoderma industry has developed greatly and today offers thousands of products to the markets. Despite the large market, there are problems with the industry which prevent it from establishing an effective market. This paper describes the current status of the world Ganoderma cultivation, products, industry and provides suggestions for facilitating further research.
Taxonomic history and controversies
Traditional Chinese books classified Ganoderma into six species with reference to the colour of the fruiting body: Sekishi (red), Shishi (violaceous), Kokushi (black), Oushi (yellow), Hakushi (white) and Seishi (blue), and were assigned based on different triterpenoid patterns (Szedlay 2002) (Table 1) . Liu (1974) compiled a monograph on Traditional Chinese Medicinal Fungi describing G. lucidum as "Lingzhi" in his book. Since then, G. lucidum was accepted as the scientific binomial of "Lingzhi" in many reports on Chinese edible and medicinal mushrooms (Ying et al. 1987 , Mao 1998 , Dai et al. 2009 , Cao et al. 2012 . Mycochemical and other studies reported different species numbers in the genus Ganoderma (Li et al. 2013 , Yan et al. 2013 , Peng et al. 2014 . However, most of the species in Ganoderma have not been subjected to systematic studies (Baby et al. 2015) . There are 445 records listed in Index Fungorum (2018) for Ganoderma, although Kirk et al. (2008) estimate that there are 80 species worldwide, but several are synonyms. The taxonomic situation within Ganoderma is unclear as the species and genus concepts are confused (Hapuarachchi et al. 2018) , because morphologically similar members are found in Fomes, Polyporus and Tomophagus (Paterson 2006) .
The traditional taxonomy of Ganodermataceae is based on its morphological traits, however, species identification has been unclear and taxonomic segregation of the genera has been controversial, since there are fundamentally different viewpoints among mycologists (Moncalvo et al. 1995 , Moncalvo & Ryvarden 1997 . Some Ganoderma collections and species have been misnamed because of the presence of heterogenic forms, taxonomic obstacles and variations in the way the genus has been subdivided (Mueller et al. 2007 ). Hence, most taxonomists regard the current nomenclatural situation of Ganodermataceae as chaotic and poorly studied (Ryvarden 1991 , Smith & Sivasithamparam 2003 , Hapuarachchi et al. 2015 , Zhou et al. 2015 , Thawthong et al. 2017 . Accordingly, it is important to establish a combination of morphological, chemotaxonomic and molecular methods to develop a more stable taxonomy (Richter et al. 2015 , Welti et al. 2015 . The collections named as G. lucidum from different parts of the world are scattered in several separated lineages in phylogenetic analyses of the genus (Wang et al. 2012) . The taxonomy of the G. lucidum complex has long been subjected to debate and even after many years of discussions, its taxonomy remains problematic due to many inconsistencies of phylogeny and morphology. Hence different opinions have been raised regarding the validity of its members (Yang & Feng 2013) .
Ecological aspects
Ganoderma species have a worldwide distribution in green ecosystems both in tropical and temperate geographical regions in Asia, Africa, America and Europe (Wang et al. 2012) . The species of Ganoderma have a wide host range, with more than 44 species from 34 genera of plants being identified as potential hosts (Venkatarayan 1936) . Plant-pathogenic and wood decaying species (Fig. 1) of Ganoderma can cause severe diseases such as stem rot, butt rot and root rot in economically important trees and perennial crops, especially in tropical countries (Coetzee et al. 2015) . Ganoderma species are white rot fungi and have ecological importance in the breakdown of woody plants for nutrient mobilization. They hold effective mechanisms of lignocellulosedecomposing enzymes useful for bioenergy production and bioremediation (Hepting 1971 , Adaskaveg et al. 1991 , Coetzee et al. 2015 , Kües et al. 2015 . Root and stem rots caused by Ganoderma species result in loss of forestry yields e.g. Areca catechu (betel nut) (Singh 1991) , Camillia sinensis (tea), Cocos nucifera (coconut) (Kinge & Mih 2015) , Elaeis guineensis (oil palm) (Glen et al. 2009 ) and Hevea brasiliensis (rubber) (Monkai et al. 2016) worldwide. Turner (1981) reported 15 species of Ganoderma from various parts of the world, such as Africa, India, Indonesia, Malaysia, North America, Papua New Guinea and Thailand as being associated with basal stem rot of oil palm, including G. applanatum, G. boninense (= G. orbiforme), G. chalceum, G. cochlear, G. lucidum, G. miniatocinctum, G. pseudoferreum (= G. philippi), G. tornatum (= G. australe) , G. tropicum and G. zonatum. Ganoderma boninense is the most aggressive pathogen to cause the basal stem rot in oil palm (Turner 1981 , Wong et al. 2012 . Different species produce different features 1028 and pathogenicity. Species identification in this genus is limited causing a crucial problem for disease management (Wong et al. 2012) .
Figure 1 -Pathogenic and wood decaying Ganoderma species. a Ganoderma applanatum found in Chinese privet plant (Ligustrum lucidum) (GACP18032701). b Ganoderma sinense (GACP18032702). c Ganoderma hoehnelianum (GACP14080913). d Ganoderma donkii (GACP18032703). e Ganoderma tropicum (GACP18032704). f Ganoderma brownii (GACP18032705). (Photographs taken by TC Wen). *GACP -The Herbarium of Guizhou University (= the Original Herbarium of Guizhou Agricultural College)
Important uses of Ganoderma
Species of Ganoderma are widely researched, because of their highly prized medicinal value, since they contain many chemical constituents with potential nutritional and therapeutic values (Hapuarachchi et al. 2016b (Fig. 4) . Ganoderma and Amauroderma include several species which possess great economic and ecological importance (Correia de Lima et al. 2014) . The fruiting bodies of Ganoderma species have gained wide popular use as dietary supplements in China, Japan, North America and other regions of the world (Paterson 2006) . Ganoderma has been used as a functional food to prevent and treat immunological diseases (Wang et al. 2012) . Several hundreds of metabolites have been obtained from the species of this family, including G. lucidum, which is the most sought after species of the genus (Dong & Han 2015) . Polysaccharides, steroids and triterpenes as the major groups followed by alkaloids, fatty acids, glycoproteins, inorganic elements, lignin, nucleosides, nucleotides, peptides, phenols, proteins, sterols and vitamins were found in G. lucidum (Boh et al. 2007 ). The bioactive constituents (Table 2 ) are reported to be responsible for anti-cancer, anti-inflammatory, anti-tumor, anti-oxidant, immunomodulatory, immunodeficiency, anti-diabetic, anti-viral, anti-bacterial, anticonvulsant, anti-fungal, antihypertensive, anti-atherosclerotic, anti-aging, anti-androgenic, anti-hepatotoxic, radical scavenging property, neuroprotection, sleep promotion, cholesterol synthesis inhibition, hypoglycemia, inhibition of lipid peroxidation/oxidative DNA damage, hepatoprotective properties, maintenance of gut health, prevention of obesity, and stimulation of probiotics (Paterson 2006 , Cao et al. 2012 , De Silva et al. 2012a , b, 2013 , Baby et al. 2015 , Bishop et al. 2015 , Liu et al. 2015b , Vyas et al. 2016 .
Generally, Ganoderma species are a good source of anti-oxidant compounds (Mau et al. 2005a , b, Rawat et al. 2013 , and such compounds can reduce oxidative damage by directly scavenging free radicals generated in the cell (Wong et al. 2004 , Agarwal et al. 2012 , Celık et al. 2014 , Rajoriya et al. 2015 , Obodai et al. 2017 . The presence of phenolic compounds are also responsible for anti-oxidant properties in many mushrooms (Ferreira et al. 2009 , Barros et al. 2008 . The presence of flavonoids specifically may have detoxification, anti-inflammatory, and curing activities for various cardiovascular diseases (Le Marchand 2002) . Many Ganoderma species exert remarkable anti-tumor activity (Jeong et al. 2008) due to the presence of many compounds such as triterpenes which can suppress growth and aggressiveness of cancer cells, polysaccharides that stimulate the anti-cancer response of immune cells and activate production of cytokines (Kuo et al. 2006 , Sliva 2006 , Smina et al. 2011 ), and flavonoids (Le Marchand 2002 ). An extract of G. lucidum inhibits distinct signalling pathways in different cancer cells (Aydemir 2002) . Ganoderma lucidum has also strong activity against human prostate cancer cells since it induces apoptosis, inhibits cell proliferation, and suppresses cell migration (Stanley et al. 2005) . Ganoderma lucidum showed activity against lymphoma, leukemia, and multiple myeloma cells (Muller et al. 2006) . Furthermore, the methanolic extract of G. applanatum has an apoptotic antitumor activity in human colon cancer cell line (Caco-2) (Elkhateeb et al. 2018) . Some Ganoderma metabolites showed also an anti-microbial activity against different pathogenic bacteria and fungi (Shikongo et al. 2013 , Singh et al. 2014 . Quereshi et al. (2010) reported the anti-bacterial activity of the acetone extract from fruiting bodies of G. lucidum against Staphylococcus aureus and against Pseudomonas aeruginosa. Polysaccharides extracted from G. lucidum exerted an anti-bacterial activity against Micrococcus luteus ATCC 10240 (Skalicka-Woźniak et al. 2012) . Hleba et al. (2014) described the anti-microbial activity of the methanolic extracts of G. lucidum against Saccharomyces cerevisiae. Furthermore, ganodermin extracted from Ganoderma lucidum exhibited anti-fungal activity against Botrytis cinerea, Fusarium oxysporum and Physalospora piricola (Wang & Ng 2006) . Polysaccharides extracted from Ganoderma species have been reported to have anti-tumor activity (Kim et al. 1980 , Miyazaki & Nishijima 1981 . Ganoderiol F and ganodermanontriol obtained from the methanol extract of the fruiting bodies of G. lucidum have anti-HIV-1 activity (El-Mekkawy et al. 1998) . Eo et al. (1999) reported anti-viral activity of G. lucidum carpophores against herpes simplex virus type 2 (HSV-2) with low cytotoxicity to host cells in vitro. Li & Wang (2006) described ganoderic acid extracted from G. lucidum as an anti-hepatitis B agent since it inhibited virus replication. Zhang et al. (2014) recorded the significant anti-viral activity of G. lucidum against enterovirus, which is the major cause of hand, foot and mouth diseases.
Ganoderma (as Lingzhi) was cultivated in a large-scale, successfully for the first time in 1969 in China (Yu & Shen 2003) and currently, the annual sale of products derived from G. lucidum is estimated to be more than US$ 2.5 billion in Asian countries, including China (Figs 2, 3), Japan, and South Korea (Li et al. 2013) . Ganoderma sinense and G. lucidum have been listed in Chinese Pharmacopeia to prevent and treat many diseases, and Ganoderma was included in American Herbal Pharmacopoeia and Therapeutic Compendium. Table 1 The six types of traditional Ganoderma and their uses (Szedlay 2002 , Wasser 2005 
G. lucidum
Polysaccharides (Ganopoly) Gao et al. 2004 Ganoderma tsugae is regarded as a health food by Chinese government (Chen et al. 2016) . Ganoderma lucidum products, from different parts of its fruiting bodies, mycelia or spores, are sold in the form of coffee, powder, tea, dietary supplements, spore products, drinks, syrups, tooth pastes, soaps and lotions and have been commercialized as food and drug supplements (Fig. 5) which enhance the body's immune system and improve metabolic functions (Chang & Buswell 1999 , Lai et al. 2004 , Singh et al. 2013 . Ganoderma lucidum was used as Bonsai products to decorate gardens, ornaments and many other art products. Awareness of Ganoderma has improved from fundamental level to artificial cultivation, large-scale cultivation and isolation of bioactive components. 
Cosmetic products based on Ganoderma
Ganoderma is a part of several cosmetics produced mainly in China, Korea, USA and some other Asian and European countries, many being used for skin lightening (Jiang 2015) . Tyrosinase enzyme is a key enzyme in the melanin formation and Ganoderma lucidum has shown tyrosinase inhibition activity (Chien et al. 2008) . Hence, many facial mask cosmetics in the market contain Ganoderma extracts which helps in skin whitening (Hyde et al. 2010) . Ganoderma lucidum combined with three other plants and zinc to stimulate hair growth in human males by lowering dihydrotestosterone or prostatic hyperplasia levels (Meehan 2015) . Table 3 lists common cosmetic products containing Ganoderma lucidum extracts.
Traditional Chinese Medicine
In ancient China, it was believed that Ganoderma had the power to enhance longevity and vivacity. Royalty considered it as a valuable mushroom and they used it when they were meditating (Ulbricht et al. 2010) . In Traditional Chinese Medicine (TCM), Ganoderma is claimed "to replenish the energy, ease the mind, and relieve cough and asthma" (Wachtel-Galor et al. 2011) . In herbal medicine, Ganoderma is used to increase energy, resist stress, or as a liver tonic (WachtelGalor et al. 2011) . Modern studies associated with animal models and molecular-based research techniques have demonstrated numerous pharmacological effects supporting these claims (Hapuarachchi et al. 2016a (Hapuarachchi et al. , b, 2017 . Inappropriate claims involving the efficacy of TCM are frequently made (Hui 1997) . Jiaogulan (Gynostemm pentaphyllum) is mixed with G. lucidum and make "Lingzhi Jiaogulan oral liquid" which helps in relieving palpitation, shortness of breath, and insomnia (Yan 2015) . There are nearly 200 medicines and compounded medicines containing Ganoderma available within China (Chen et al. 2016) . Modern research revealed that triterpenoids and polysaccharides were responsible for the pharmacological effects mentioned above. However, due to the difficulty in obtaining large amounts of the pure triterpenoids and polysaccharides, double-blind clinical data of the active components are limited. No natural products or extracts from Ganoderma have been reported to enter clinical trial (Cheng et al. 2013 .
Medicated foods and dietary supplements
The total number of publications on Ganoderma in the world has exceeded 10,000 with 7,000 related patents. Over 1,000 Ganoderma health food products are certified by Chinese government (Chen et al. 2016) . Ganoderma lucidum is used as the material of functional food in daily life such as soup, tea, wine and yoghourt (Dong & Han 2015) . This species is used with ginseng (Panax ginseng) to make soups. These soups are useful for soothing the nerves, relieving asthma, and strengthening the immune system (Zhao 2015) . Ganoderma lucidum is mixed with sanqi (Panax nostoginseng) to make herbal Sanqi wine which helps to promote blood circulation and soothe nerves (Zhao 2015) . Ganoderma lucidum alone or combined with other herbs such as Chinese yam (Dioscorea opposite), magnolia berry (Schisandra chinensis), and desert-broomrape (Cistanche deserticola) can be used in herbal wine for balancing the body and anti-aging process (Dong & Han 2015) . Tea is prepared by G. lucidum alone or mixed with other herbs such as Japanese honeysuckle (Lonicera japonica), Chinese hawberry (Crataegus pinnatifida) and wolfberry (Lycium barbarum) which helps in modulating immunity to keep the body in balance (Dong & Han 2015) .
Cultivation
Commercial cultivation of Ganoderma has been introduced worldwide, especially in tropical Asian countries to meet the gradually increasing demand of the mushroom as a natural medicine (Wachtel-Galor et al. 2011) . Wild Ganoderma is difficult to collect and to maintain its quality. In ancient times, Ganoderma was collected from the wild and consumed only by wealthy people, but a large proportion is cultivated today for the general population. Artificial cultivation of Ganoderma was attempted in 1937 (Perumal 2009 ). However, the first successful cultivation of Ganoderma was performed in 1969 with the use of a spore separation cultivation method by a Chinese technician in the Institute of Microbiology, Chinese Academy of Sciences, Beijing (Yu & Shen 2003) . Since then, the cultivation of Ganoderma has been popular in China and other Asian countries, such as Japan and Korea (Li et al. 2016a ). Traditional cultivation (since 1969) was based on inoculating one meter long natural logs without sterilization, which were then buried in a shallow trough (Pegler 2002) . Most broad-leaf hardwoods can be used to cultivate Ganoderma species and logs are cut from living trees (Chen 2002) . Fruiting bodies took 6-24 months to emerge, but cropping could continue for five years (Pegler 2002) . Since late 1980s, new methods have been developed that use short logs (15 cm or less) (Chen 2002) . Today, this method is followed by most Ganoderma natural-log growers in China, Japan and Korea (Chen & Chen 2004) . As it takes several months to produce the fruiting body, mycelia-based and culture broth-based products have been considered as methods to ensure quality control and for continuous production throughout the year (Sanodiya et al. 2009 ). Different species of Ganoderma need different conditions for growth and cultivation (Mayzumi et al. 1997 ). There are several other methods that have been trialed to cultivate Ganoderma such as basswood cultivation (Zhang et al. 2004) , sawdust cultivation and substituted cultivation. Artificial cultivation of G. lucidum has been achieved using substrates such as grain, sawdust, wood logs (Chang & Buswell 1999 Various ornamental growth forms, including antler-like structures, can be produced by altering the growing conditions, especially temperature and the carbon dioxide volume (Pegler 2002) . Current methods involved in commercial production of Ganoderma, include wood log, short basswood segment, tree stump, sawdust bag, and bottle procedures (Mayzumi et al. 1997 , Lin & Zhou 1999 , Erkel 2009 , Chen 1999 , Han et al. 2008 . Natural log cultivation produces Ganoderma mushrooms with superior quality and gets best prices in the markets of Southeast Asia. However, the yield could be lower, and the production time could be little more extended than sawdust synthetic log cultivation (Chen & Chao 1997) . It is important to conserve the forests where logs are collected, and this is of significant environmental concern (Chen & Chen 2004) . Nowadays G. lucidum is not the only species in this genus grown for a commercial purpose worldwide, but also G. applanatum, G. capense, G. sinense, G. tsugae (Chen & Chen 2004) and G. neojaponicum (Tan 2015) are cultivated in farms.
Global Marketing
Ganoderma based products have attracted a great deal of attention during the last decade in Europe, Malaysia, North America and Singapore. China, Japan and Korea are the main producers and suppliers of Ganoderma based products (Chang & Mills 2004) (Table 4 ). The total Ganoderma production of Japan during 1995 was estimated approximately 500 MT. In 1997, the worldwide G. lucidum production was 4300 MT, and 3000 MT were from China, while 1500 MT were exported to Japan, Korea, Singapore and Taiwan. The remaining 1300 MT were produced mainly in Korea, Taiwan, Japan, Thailand, US, Malaysia, Vietnam, Indonesia and Sri Lanka (Zhou & Gao 2002) . The DXN Group in Malaysia produced 70 MT of Ganoderma and accounted for 1% of the global production in 2001 (DXN Holdings' IPO listing Reports).
The total world market for Ganoderma based natural health care products was 1628 million US dollars in 1995 (Chang & Buswell 1999) . In 2004, Ganoderma lucidum worldwide production was approximately 5000-6000 MT and more than half was produced by China (Rai 2003 , Lai et al. 2004 . The China Edible Fungi Association recorded that Ganoderma production in China was 36700 and 49200 MT in 2002 and 2003 , respectively (Banuelos & Lin 2009 ). However, there are some problems with Ganoderma based products because of low reproducibility and poor quality control. Various reasons such as seasonal variations, different soil conditions and stage of fruiting body development weaken the product quality. Hence, it is important to develop acceptable and
Figure 4 -Medicinally important Ganoderma species. a Ganoderma sinense (GACP14081236). b Ganoderma calidophilum (GACP15081036). c Ganoderma orbiforme (GACP1706211). d Ganoderma flexipes (GACP17102301). e Ganoderma resinaceum (GACP HNU58). f Ganoderma multiplicatum (GACP14081328). *GACP -The Herbarium of Guizhou University (= the Original Herbarium of Guizhou Agricultural College)
Figure 5 -Ganoderma products used as drugs and food supplements in China. a Ganoderma lucidum compound capsules (Chongqing Taiji Industry (Group) Co. Ltd). b Ganoderma lucidum syrups (Guizhou Shunjian Pharmaceutical Co. Ltd). c Ganoderma lucidum spore powder capsules enriched with Se (Guizhou Lingkangshi Biological Technology Co. Ltd). d Ganoderma lucidum spore powder (Yunnan Xianghui Pharmaceutical Co. Ltd). e Broken G. lucidum spore powder oil capsules (FGTZ Biotechnology Company). f Broken G. lucidum spore powder (Chengdu Dujiangyan Chunsheng Chinese Herbal Pieces Co. Ltd). g Ganoderma lucidum fruiting body slices (Sichuan Zibo Pharmaceutical Co. Ltd) (Photographs taken by TC Wen). reproducible protocols for manufacturing processes to ensure high quality, standard and safe Ganoderma products (Chang & Mills 2004) . Good laboratory, agriculture, manufacturing, production and clinical practices are essential to achieve quality Ganoderma products (Chang & Mills 2004) . Ganoderma products are divided into three types; developmental products based on Ganoderma fruiting bodies (Wasser 2011) , mycelia (He 2000) , and spore powder (Xie et al. 2002) . A variety of Ganoderma products have been commercialized and it is estimated that at least 100 brands and over 780 products are sold in the world markets (Lai et al. 2004 , Li et al. 2016a . USA is the largest market for Ganoderma and related products (Perumal 2009 ). Li et al. (2016a showed China is the largest producer and exporter with a capacity over 110,000 MT/year of fruiting bodies, slices, and spore powders as most popular products among consumers. Even though China accounts for 70% of the world's production, it exports less than 5% of total production. Most manufacturing facilities in China do not possess internationally recognized GMP (Good Manufacturing Practice) certifications for acceptance in international markets (Pang 2002 ). There are more than 100 research institutes that specialize in the study of Ganoderma, and more than 200 factories involved in the production of drugs and nutraceuticals in China. Furthermore, many patented products have been marketed upon the preparation of anti-tumor, liver function accelerant, lowering of blood pressure, hypoglycemic activity, lowering of cholesterol levels, treatment of chronic bronchitis, immunomodulator, lysozyme as antibiotic and shampoo and body shampoo (Xie et al. 2002) . In the early 1980s, there were some Ganoderma based products on the international market, such as decoction, syrup, tablet, and injection liquid. In the early 1990s, 90 brands of Ganoderma products were registered and marketed internationally (Lin 2000) . However, today it varies from drugs, health liquor, and Ganoderma dietary supplements to cosmetology products. These products are sold as prescription drugs in some Asian countries, however, mostly they are advertised as dietary supplements globally (Lai et al. 2004 ). Global consumption is estimated at several thousand tonnes, and the demand is growing swiftly (Wachtel-Galor et al. 2011) . Numerous G. lucidum products, prepared from different parts of the mushroom, are currently available on the market (Chang & Buswell 2008) . However, these products do not yet fulfill the customer satisfaction.
Draw backs and future trends
A number of challenges have to be addressed regarding this industry. The systematics and taxonomy of Ganoderma species needs to be studied and confirmed. Homogeneity of products, lack of highly value-added products, poor quality and high prices are also major problems (Li et al. 2016a ). The quality standard of the fungus and management of Ganoderma products must be improved and include the identification and control of the bioactive components, any hazardous and noxious substances such as heavy metals and residual pesticides and, moreover, trials are needed to develop new product formulations (Zhou et al. 2011 , Hobbs 2017 . Recently, a group of researchers showed that most of the Ganoderma products in USA lacked characteristic triterpenoids and contained a starch like -polysaccharide profile that was inconsistent with G. lucidum (Wu et al. 2017 ). Furthermore, it was suggested that the quality consistency of G. lucidum dietary supplements collected in USA was extremely poor and requires careful investigation (Wu et al. 2017 ). All companies manufacturing Ganoderma based products should be accredited according to international standards. There has been a trend and significant increase in developing natural drugs to prevent and treat many immunological diseases over the last few decades. There have been some reports of human trials using Ganoderma as a direct control agent for various diseases but scientific evidence is inconclusive (Gao et al. 2003a , b, Zhao et al. 2011 , Zhou et al. 2014 , Baby et al. 2015 . Clinical trials were successful most of the time together with Ganoderma preparation, but more in-depth investigation and accurate scientific evidence are still required, especially for double-blind clinical data. Factors like small sample size, lack of a placebo control group, lack of information regarding long term treatment of the drug, age, patient's gender and side effects, standard method of extraction of Ganoderma, standard dosage, and number of patients treated weaken the validity of the results ). However, well-designed in vivo tests and randomized controlled clinical studies with Ganoderma can provide statistically significant results to confirm the efficacy and safety of Ganoderma preparations in order to incorporate Ganoderma as an integrative therapy. Clarification of active ingredients, isolation and purification of individual compounds should be carried out and this will enable the active ingredients within nutriceutical products to be measured and to understand whether the beneficial compounds in Ganoderma act synergistically or independently. Hence, it will help to explain potential synergistic effects and establish safe and beneficial dose ranges of active ingredients for each disease type. Further, standardization and quality control of Ganoderma strains, cultivation processes, extracts and commercial formulations, are needed for wide acceptance of Ganoderma as a natural product for use in the prevention and treatment of various diseases (Hapuarachchi et al. 2016b) .
Breeding of new Ganoderma strains will enhance the development of strains with higher yield and resistance to diseases, which in turn will increase productivity and reduce the use of chemicals for pest control. Modern engineering technologies, such as computerized control systems
